LA HB233

Creates the "Louisiana Drug Manufacturing Repatriation Act" providing income tax credits to pharmaceutical manufacturers that close facilities in Canada, Mexico, China, India, Singapore, the UK, or the European Union and relocate operations to Louisiana

Credit amounts range from 0.5% to 2.5% of property costs based on IRS depreciation recovery periods (3-year property at 0.5% up to 15-year or greater property at 2.5%)

Maximum credit capped at $10 million per qualifying taxpayer per taxable year, with unused credits carried forward up to 10 years

Qualifying property must be tangible manufacturing equipment or production software used as an integral part of pharmaceutical manufacturing, with original use commencing in Louisiana

Taxpayers claiming this credit are prohibited from receiving any other state tax credits, exemptions, or benefits for the same activity; effective January 1, 2026